Pharmacokinetics-Pharmacodynamics (PK-PD) Modeling: A translational path to brain-targeted drug delivery

Ashok Aspatwar,Ratul Bhowmik,Ranajit Nath,Bhabani Sankar Satapathy,Puja Saha,Rajesh Ghosh,Seppo Parkkila

DOI: https://doi.org/10.26434/chemrxiv-2024-wvkr6

2024-07-05

Abstract:Pharmacokinetic-pharmacodynamics (PK/PD) modeling has been recognized as an essential tool for the planning and execution of clinical pharmacology investigations throughout the formulation development process. The utilization of PK/PD modeling to optimize dosage recommendations and therapeutic medication monitoring is on the rise, and PK/PD model-based dose individualization is going to play a crucial role in personalized medicine. In recent years, higher costs and low productivity in drug development have got a lot of attention. Fewer than 10% of innovative medications that survive clinical trials are commercialized, while many more fail in preclinical research. Based on preclinical and clinical data, the FDA now defines model-based drug development as a key tool in the assessment of therapeutic efficacy and safety of medications. As successful drug delivery to central nervous system (CNS) diseases has been a tough challenge, effective use of PK/PD models can permit merging data from clinical trials with quantified exposure and provide highly convincing explanations for disparities in the results of distinct investigations. To improve CNS therapies and drug development, details of inter-species and inter-condition variations are needed to enable target site pharmacokinetics and associated CNS effects between disease states. The present review covers the potential of PK/PD modeling in the current scenario of drug development with a special emphasis on CNS-based targeted delivery. Additionally, challenges associated with the field have also been addressed.

Chemistry

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the efficiency of drug delivery for central nervous system (CNS) diseases. Specifically, the paper explores the application of pharmacokinetic - pharmacodynamic (PK - PD) modeling in optimizing drug dose recommendation and therapeutic drug monitoring, especially in brain - targeted drug delivery. The paper emphasizes the importance of PK - PD modeling in personalized medicine and discusses how to interpret the differences between different research results by integrating clinical trial data and quantifying exposure. In addition, the paper also focuses on the details of cross - species and cross - condition changes, which are crucial for understanding the pharmacokinetics at the target site and related CNS effects. The paper points out that successful CNS drug delivery has been one of the biggest challenges for drug formulation scientists. In order to achieve the expected effect, CNS - targeted drug research focuses on developing new technologies to improve drug targeting and bioavailability. Therefore, the mechanisms of drug absorption and distribution after administration by new - type drug delivery devices become extremely complex. Understanding the behavior of these complex drug delivery systems in the body is crucial for rational drug administration and formulating effective CNS delivery dose strategies. Overall, this paper aims to analyze in - vivo studies of the concentration - effect relationship of CNS - acting drugs in animals and humans, as well as the application of PK - PD modeling methods. At the same time, the paper also discusses the challenges and the latest progress in this field.

Pharmacokinetics-Pharmacodynamics (PK-PD) Modeling: A translational path to brain-targeted drug delivery

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics

PBPK modeling and simulation in drug research and development

Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach

Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development

Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability

Model-Based Virtual PK/PD Exploration and Machine Learning Approach to Define PK Drivers in Early Drug Discovery

The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives

Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery

Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases

The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives

Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials

Entering the era of computationally driven drug development

Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics

Utilizing Multifaceted Approaches to Target Drug Delivery in the Brain: From Nanoparticles to Biological Therapies

Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration

Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges